Abstract

Cell therapies are becoming increasingly widely used, and their production and cryopreservation should take place under tightly controlled GMP conditions, with minimal batch-to-batch variation. One potential source of variation is in the thawing of cryopreserved samples, typically carried out in water baths. This study looks at an alternative, dry thawing, to minimise variability in the thawing of a cryopreserved cell therapy, and compares the cellular outcome on thaw. Factors such as storage time, patient age, and gender are considered in terms of cryopreservation and thawing outcomes. Cryopreserved leukapheresis samples from 41 donors, frozen by the same protocol and stored for up to 17 years, have been thawed using automated, water-free equipment and by conventional wet thawing using a water bath. Post-thaw viability, assessed by both trypan blue and flow cytometry, showed no significant differences between the techniques. Similarly, there was no negative effect of the duration of frozen storage, donor age at sample collection or donor gender on post-thaw viability using either thawing method. The implication of these results is that the cryopreservation protocol chosen initially remains robust and appropriate for use with a wide range of donors. The positive response of the samples to water-free thawing offers potential benefits for clinical situations by removing the subjective element inherent in water bath thawing and eliminating possible contamination issues.

Highlights

  • The use of cell therapies such as CAR T cells as an effective treatment for a range of conditions is growing rapidly, harnessing the power of the immune system to fight cancers [1]

  • For CD34+ post-thaw cell viability, the water-free thawing method gave on average higher results than the wet thawing method with a correlation coefficient of 0.834

  • Average trypan blue viability was 69.4 ± 19.2%, which was significantly higher than the CD34+ viability at 49.2 ± 20.4%, (p-value < 0.05)

Read more

Summary

Introduction

The use of cell therapies such as CAR T cells as an effective treatment for a range of conditions is growing rapidly, harnessing the power of the immune system to fight cancers [1]. Sourcing the initial biological sample to create the preparation used for treatment is the first, key element in this process. For blood-based therapies this is commonly taken from cord blood, or an apheresis sample, for autologous treatments or allografts [2]. Factors impacting storage and thawing of haematopoietic cells: Storage time, age, gender, and wet/dry thawing

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.